XNASOM
Market cap73mUSD
Jan 03, Last price
1.40USD
1D
19.66%
1Q
125.44%
IPO
-97.67%
Name
Outset Medical Inc
Chart & Performance
P/E
—
P/S
0.56
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.51%
Rev. gr., 5y
130.43%
Revenues
130m
+13.00%
Net income
-173m
L+6.04%
CFO
-131m
L-9.85%
Earnings
Jan 06, 2025
Profile
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 130,376 13.00% | 115,375 12.45% | ||||
Cost of revenue | 300,146 | 276,394 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (169,770) | (161,019) | ||||
NOPBT Margin | ||||||
Operating Taxes | 523 | 295 | ||||
Tax Rate | ||||||
NOPAT | (170,293) | (161,314) | ||||
Net income | (172,797) 6.04% | (162,956) 23.51% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 10,427 | 8,042 | ||||
BB yield | -3.89% | -0.65% | ||||
| Debt | ||||||
Debt current | 3,186 | 1,318 | ||||
Long-term debt | 140,670 | 108,806 | ||||
Deferred revenue | 101 | 151 | ||||
Other long-term liabilities | 896 | 113 | ||||
Net debt | (59,468) | (180,689) | ||||
| Cash flow | ||||||
Cash from operating activities | (131,373) | (145,729) | ||||
CAPEX | (3,440) | (8,325) | ||||
Cash from investing activities | 83,026 | (66,295) | ||||
Cash from financing activities | 43,652 | 72,898 | ||||
FCF | (167,194) | (178,854) | ||||
| Balance | ||||||
Cash | 203,324 | 287,502 | ||||
Long term investments | 3,311 | |||||
Excess cash | 196,805 | 285,044 | ||||
Stockholders' equity | (961,629) | (789,466) | ||||
Invested Capital | 1,223,293 | 1,138,950 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 49,588 | 48,161 | ||||
Price | 5.41 -79.05% | 25.82 -43.98% | ||||
Market cap | 268,271 -78.43% | 1,243,517 -40.82% | ||||
EV | 208,803 | 1,062,828 | ||||
EBITDA | (163,960) | (155,850) | ||||
EV/EBITDA | ||||||
Interest | 12,675 | 3,566 | ||||
Interest/NOPBT | ||||||